Biomarkers: Technologies and Global Markets

The global market for biomarkers should grow from $43.3 billion in 2020 to $92.1 billion by 2025, at compound annual growth rate (CAGR) of 16.3% for the period of 2020-2025.

Report Includes

• 48 data tables and 25 additional tables
• An updated review and current landscape of the global biomarkers market
• Analyses of the global market trends, with data from 2018-2020, and projections of compound annual growth rates (CAGRs) through 2025
• Estimation of market size and market potential for global biomarkers market, and corresponding market share analysis by product type, technology type, therapeutic area, end user and geographic region for each market segment
• Latest information on market opportunities and drivers, industry structure, regulatory frameworks, clinical trials and technological updates which are affecting the overall market growth
• Identification of the leading biotechnology companies poised to introduce products during the forecast period, their impact on the face of the competitive environment and research priorities
• Discussion of major types of biomarkers and their use in clinical trial assessment, drug discovery and development, and therapeutics
• Review of patents issued for biomarker technologies and deep dive of patent data by year, technology type, application, company, assignee and applicant country
• Profile description of major market players, including Abbott Laboratories Ltd., Bayer AG, Bio-Rad Laboratories Inc., Canon Medical Corp., and Luminex Corp.

The global market for biomarkers should grow from $78.9 billion in 2018 to $136.5 billion by 2023 at a compound annual growth rate (CAGR) of 11.6% from 2018 through 2023.

Report Includes

• 70 data tables and 42 additional tables
• Industry analysis of the global biomarkers market
• Country specific data and analysis for United States, Canada, Mexico, France, Germany, U.K., China, India, Japan, Middle East and Africa
• Characterization and quantification of the market potential for biomarkers by segment, product type, therapeutic area and geographical region
• Encompassing details of major types of biomarkers and their use in clinical and research applications
• Examination of regional market dynamics with a focus on regulatory development, key technology updates and major drivers impacting the global market
• Assessment of the leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
• Detailed profiles of the leading biomarkers' manufacturers, including Abbott Laboratories, Bayer Group, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline and Novartis AG

The global biomarkers market has grown to $39.4 billion in 2014 from $29.3 billion in 2013. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 13.8% from 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 billion in 2020.

Report Includes

• An overview of the global markets for biomarkers.
• Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2020.
• Assessments of companies poised to introduce products during the forecast period and discussion on how these introductions will change the face of the competitive environment.
• A range of information from detailed product analyses within disease subsegments to overall industry trends.
• A look at how market growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia.
• Profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.

The global biomarkers market is expected to grow from $29.3 billion in 2013 to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.

Report Includes

• An overview of the global market for biomarkers.
• Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Assessments of companies poised to introduce products during the forecast period and discussion on how these introductions will change the face of the competitive environment.
• A range of information from detailed product analyses within disease subsegments to overall industry trends.
• A look at how market growth is expected in emerging geographies, driven by the growing middle class in emerging countries such as India, China, Brazil, and Russia.
• Comprehensive profiles of manufacturers of leading products as well as biotechnology companies with novel products in development.

In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 at a 5-year compound annual growth rate (CAGR) of 19.8%.

• The global market for biomarkers increased from $4.8 billion in 2006 to an estimated $5.6 billion by the end of 2007. It should reach $12.8 billion by 2012, a compound annual growth rate (CAGR) of 18%.
• Global revenues for biomarker discovery technologies tailored to drug discovery, preclinical studies of drug development and diagnostics research applications accounted for 47.9% of the total market in 2007. Their value is projected to grow at a CAGR of 16.9% and is expected to reach a little less than $6 billion in 2012.
• The use of biomarkers in oncology therapeutics is likely to be one of the foremost priorities in clinical trials in the next 3 to 7 years followed by cardiovascular applications.